IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Amkay Products IPO is a book build IPO listing on BSE SME exchange. The company is based in Mumbai and caters to Healthcare sector. Hem Securities is the merchant banker of Amkay Products IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 14th February 2024.
Amkay Products IPO posted revenues of Rs 31.80 crores and PAT of Rs 2.87 crores in FY24 on annualised basis.Financial results of Amkay Products IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Amkay Products IPO PAT Margin is 9.45%, ROCE (Return on Capital Employed) is 21.54% as per latest financial. The below table shows Amkay Products IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Amkay Products IPO is Rs 47.61 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Amkay Products IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Amkay Products IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Amkay Products IPO is ₹47.61 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Amkay Products IPO has a Price-to-Earnings (PE) ratio of 16.58 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Amkay Products IPO reported revenue of ₹31.80 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Amkay Products IPO provide insights into sales growth, market demand, and business scalability.
Amkay Products recorded an EBITDA of ₹ 3.37 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Amkay Products Profit After Tax (PAT) is ₹2.87 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 30.33 Cr.
EBITDA Margin:
11.12
%
Net Worth: ₹ 9.87 Cr.
Market Capitalisation:
₹ 47.61 Cr.
P/E:
16.58 times
P/BV: 2.12 times
EV/EBITDA: 15.21 times
Amkay Products operates in Healthcare and Healthcare Products. The Issue is listed on BSE SME in May, 2024. Amkay Products IPO size was 12.61 with Issue price of 55.00 .
Merchant Banker(s) of Amkay Products IPO: Hem Securities Limited
Amkay Products IPO subscription was 748.03 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Amkay Products IPO listed at a listing price of 109.72 against the offer price of 55.00.
The current market price of Amkay Products is 45.90.
Why Us?
